Discovery

Eligo Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million

Lead Product(s): EB005

Therapeutic Area: Dermatology Product Name: EB005

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: $224.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 11, 2021

Details:

Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.

Almirall

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Outsourcing in Clinical Trials

Participation Not Confirmed

Update your events

Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: University of Dundee

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 08, 2020

Details:

The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.